Biotechnology firm Illumina and genomics company GenoScreen have introduced a new package that combines products from Illumina with the GenoScreen Deeplex Myc-TB assay, a next-generation sequencing (NGS)-based test for Tuberculosis (TB).
As a targeted NGS-based test, the Deeplex Myc-TB assay enables quick and broad identification of anti-TB drug resistance.
Developed and manufactured by GenoScreen since 2019, the assay uses a culture-free approach to detect TB mycobacteria, as well as more than 100 non-TB mycobacterial species.
